AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01209026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin placebo
Description: Film coated oral tablet
Study NCT04620213 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phentolamine Ophthalmic Solution Vehicle (Placebo)
Description: Topical sterile ophthalmic solution
Study NCT00712400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 0.005%, Xalatan®
Description: Substance: Latanoprost 0.005%, Xalatan® (Pharmacia Austria Ges.m.b.H. Oberlaaer Straße 251, 1101 Vienna) Dosage form: topical application in one eye Dosage: 1 drop in the evening for 14 days
Study NCT00712400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Substance: Vehicle to latanoprost (eyedrops containing the same stabilizers as latanoprost, but no active drug) Dosage form: topical application in one eye Dosage: 1 drop in the evening for 14 days
Study NCT01473680 — intervention group
Intervention type: OTHER
Intervention: EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire
Description: Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
Study NCT00564057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: candesartan
Description: tablet 8-16 mg once daily, one year
Study NCT00564057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lercanidipine
Description: tablets 10-20 mg once daily, one year
Study NCT04347668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: VR requires the user to use a multi-projected in their own room using BroomX to generate realistic images, sounds and other sensations that simulate a user's physical presence in a virtual or imaginary environment
Study NCT04347668 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: meals, engagement in scheduled and non-scheduled programs such as exercise, and activities, groups. Residents are supported in their activities of daily living, and social engagement. Specific interventions based on resident needs are supported in a Dementia capable environment.
Study NCT01317550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: 150 mg by mouth once a day for a 10 week cycle.
Study NCT01317550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules taken by mouth once a day for a 10 week cycle.
Study NCT01317550 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules taken by mouth once a day for a 10 week cycle.
Study NCT01317550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 100 mg by mouth twice a day for a 10 week cycle.
Study NCT01317550 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Completion of symptom questionnaire before chemoradiation, then once a week during Weeks 1-16, takes up to 5 minutes to complete.
Study NCT01317550 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Completion of symptom questionnaire before chemoradiation, then once a week during Weeks 1-16, takes up to 5 minutes to complete.
Study NCT03963167 — intervention group
Intervention type: DRUG
Intervention: BDP/FF/G fixed combination
Description: Fixed combination of Inhaled Corticosteroid (ICS) / Long-acting β2-agonist (LABA) / long-acting muscarinic antagonist (LAMA) that contains Beclometasone dipropionate (BDP), Formoterol fumarate (FF) and Glycopyrronium (G).
Study NCT02551510 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: Skin incision closure with standard subcuticular technique
Study NCT02551510 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Experimental: Histoacryl®
Description: Skin incision closure with topic skin adhesive Histoacryl® Flexible (n-Butyl-2-Cyanoacrylate Monomer)
Study NCT03741166 — intervention group
Intervention type: OTHER
Intervention: Blood Sample Collection
Description: Subjects participating in the study will have blood drawn at enrollment.
Study NCT00488787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal ketamine
Description: low dose
Study NCT03071757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-368
Description: Intravenous infusion
Study NCT00488787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal ketamine
Description: medium dose
Study NCT00488787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal ketamine
Description: high dose
Study NCT00488787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01505998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine Besylate/Benazepril HCl
Description: Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules
Study NCT01505998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine Besylate/Benazepril HCl
Description: Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules
Study NCT03219866 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nebulizers
Description: Patients treated and discharged on nebulized bronchodilators
Study NCT03219866 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry Powder Inhaler
Description: Patients treated and discharged on Dry Powder Inhalers
Study NCT03219866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brovana
Description: Subjects will receive a long-acting B2-agonist(LABA; Brovana, twice daily)
Study NCT03219866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulmicort
Description: Subjects will receive a corticosteroid (ICS; Pulmicort, twice daily)
Study NCT03219866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atrovent
Description: Subjects will receive a short-acting anti-cholinergic (SAMA; Atrovent, three times a day)
Study NCT03071757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-181
Description: Intravenous infusion
Study NCT02908490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sildenafil
Description: Sildenafil 50 mg once daily
Study NCT02908490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Sildenafil 50 mg once daily
Study NCT02908490 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily with same size, shape, color, and texture as Sildenafil 50 mg pill
Study NCT02908490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo once daily with same size, shape, color, and texture as Sildenafil 50 mg pill
Study NCT00756912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5564
Description: Three dose levels of Eritoran IV over 14 days for a total of 32, 96, and 224 mg over 14 days.
Study NCT04664764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degludec
Description: Basal insulin comparison
Study NCT04664764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Description: Basal insulin comparison
Study NCT04664764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH insulin
Description: Basal insulin comparison
Study NCT01056302 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical repair of mandibular fractures
Description: Patients will undergo whatever needed surgical repair of maxillofacial trauma that is necessary. Records such as CT imaging and plaster models of the jaws will be utilized in the standard way to plan and carry out the surgery. The CT scan will also be used within the visuohaptic computational environment to develop and evaluate the user interface. The amount of time taken to work up and plan surgery using standard surgical practice and using the computational platform will be compared. Real surgical outcome will be compared to the simulated surgical outcome using the proposed software tool.
Study NCT02651909 — intervention group
Intervention type: OTHER
Intervention: blood sampling
Description: blood sampling for TEG analysis, Thrombin time, thrombin generation, PT with neoplastine, ecarin chromogenic assay, anti-factor Xa (rivaroxaban assay
Study NCT01057875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: caffeine
Description: Starbuck's Grande Pike Roast coffee
Study NCT01057875 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No caffeine
Description: Starbuck's Grande Pike Roast Decaffeinated Coffee
Study NCT05704569 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of multiple biomarkers
Description: All patients were tested for glucose and cholesterol levels. The capillary blood glucose level was measured by an electrochemical method using an Accu-Chek Active by AkkuChek blood glucose meter. The DM was considered to be verified when there were criteria which the World Health Organization (WHO) set in 2001: glucose concentration in whole blood is >6.1 mmol/l, and glucose concentration is >11.1 mmol/l in random measurement. Plasma for the study was obtained via the standard phlebotomy technique from ethylenediaminetetraacetic acid (EDTA) anticoagulants. Plasma was aliquoted into cryovials and got frozen quickly. The samples were stored in a low-temperature refrigerator (-70°C) until the study commencement (up to 3 months). All biomarkers were measured by magnetic bead-based multiplex immunofluorescence assay through the Xmap technology using the Milliplex map Human CVD Magnetic Bead Panel 1 (Millipore)
Study NCT04442035 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5-element music therapy
Description: participants were treated by TCM five-phase music therapy for not less than 30 minutes per day, and group music therapy was performed every three weeks. In addition, the therapeutic schedule is composed of treatment time (1pm-2pm, 9pm-11pm), frequency treatment (two times a day), intervention (10-15 minutes in the afternoon, 30 minutes in the evening) and content (individuals: dialectical selection of music; groups: community singing, every three weeks).
Study NCT03135119 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TF-CBT
Description: TF-CBT is typically described as including 3 phases, each focusing on a common goal and encompassing a third of treatment (4 sessions). The first phase focuses on skills-building and includes psychoeducation, parenting skills training, relaxation skills training, affect modulation skills training, and cognitive coping skills training. The second phase involves focused gradual exposure activities, including construction of a narrative account of the child's maltreatment experiences and cognitive processing of maladaptive thoughts. The third phase emphasizes the child's mastery over environmental reminders of the maltreatment and includes sharing the trauma narrative with the caregiver, in vivo exposure to physical stimuli, and enhancing future development.
Study NCT03135119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TF-CBT+AAT
Description: TF-CBT, as described in the other arm, with animal-assisted therapy as an adjunct intervention. During the administration of TF-CBT, a certified service dog will be in the room and the participant may elect to interact with the dog as various points throughout the sessions.
Study NCT01478048 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Solution; Intravenous (IV); 10 mg/kg; (Cycles 1 \& 2: Days 1, 8 \& 15; Cycles 3-8: Days 1 \& 11; Cycle 9+: Days 1 \& 15); Until subject meets criteria for discontinuation of study drug
Study NCT01478048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Solution; IV; 1.3 mg/m2; (Cycles 1 - 8: Days 1, 4, 8, 11; Cycles 9+: Days 1, 8, 15); Until subject meets criteria for discontinuation of study drug
Study NCT04221477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered by IV infusion at a dose of 1000 mg at Baseline and Weeks 2, 24, 26, 50 (group 2: placebo), and 52 and subsequently from Week 80 and every 6 months thereafter, based on response.
Study NCT04221477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered by IV infusion at a dose of 1000 mg at Baseline and Weeks 2, 24, 26, 50 (group 2: placebo), and 52 and subsequently from Week 80 and every 6 months thereafter, based on response.
Study NCT04221477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF
Description: MMF willl be administered at a target dose of 2.0 - 2.5 g/day in divided doses through Week 80.
Study NCT04221477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MMF
Description: MMF willl be administered at a target dose of 2.0 - 2.5 g/day in divided doses through Week 80.
Study NCT04221477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 0.5 mg/kg/day (maximum 60 mg/day) will be started on Day 2. Beginning on Day 15, prednisone will be tapered to 5 mg/day and continued until Week 80.
Study NCT04221477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Prednisone 0.5 mg/kg/day (maximum 60 mg/day) will be started on Day 2. Beginning on Day 15, prednisone will be tapered to 5 mg/day and continued until Week 80.
Study NCT01478048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Solution; IV; 1.3 mg/m2; (Cycles 1 - 8: Days 1, 4, 8, 11; Cycles 9+: Days 1, 8, 15); Until subject meets criteria for discontinuation of study drug
Study NCT01478048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets; Oral; 20 mg; (Cycles 1\& 2: once daily on Days 2, 4, 5, 8, 9, 11; Cycles 3-8: once daily on Days 2, 4, 5, 9, 12; Cycles 9+: once daily on Days 2, 8, 9, 16); Until subject meets criteria for discontinuation of study drug
Study NCT01478048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets; Oral; 8 mg; (Cycles 1\& 2: Days 1, 8, 15; Cycles 3-8: Days 1 \&11; Cycles 9+; Days 1 \& 15); Until subject meets criteria for discontinuation of study drug
Study NCT01478048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Solution; IV; 8 mg; (Cycles 1\& 2: Days 1, 8, 15; Cycles 3-8: Days 1 \&11; Cycles 9+; Days 1 \& 15); Until subject meets criteria for discontinuation of study drug
Study NCT01478048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Tablets; Oral; 20 mg; (Cycles 1-8 once daily on Days 1, 2, 4, 5, 8, 9, 11, 12; Cycles 9+ once daily on Days 1, 2, 8, 9, 15, 16); Until subject meets criteria for discontinuation of study drug
Study NCT03219866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advair Diskus
Description: Subjects will receive a LABA/ICS (Advair Diskus, twice daily)
Study NCT03219866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spiriva HandiHaler
Description: Subjects will receive a long-acting anticholinergic (LAMA-Spiriva Handihaler, once daily)
Study NCT03170752 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiovascular Assessment Screening Program (CASP)
Description: Step 1. Identification of patients; Step 2. Screening utilizing appropriate tools; and Step 3. Actions to follow up on the screening results.
Study NCT01762566 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: wheat
Description: wheat is administered blindly versus placebo in capsules once
Study NCT01762566 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: wheat
Description: wheat is administered blindly versus placebo in capsules once
Study NCT01762566 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: xylose
Description: placebo (xylose) will be administered blindly versus wheat in a capsule once
Study NCT03873740 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 inactived vaccine（Vero cells）
Description: The EV71 inactived vaccine（Vero cells） was manufactured by Sinovac Biotech Co., Ltd.
Study NCT03873740 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 inactived vaccine（Human diploid cells）
Description: The EV71 inactived vaccine（Human diploid cells） was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.
Study NCT02447237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary counselling
Description: the participants will receive dietary counselling in fulfilling their need of energy and protein according to the group they are randomized to (either solid or liquid food).
Study NCT02447237 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: dietary counselling
Description: the participants will receive dietary counselling in fulfilling their need of energy and protein according to the group they are randomized to (either solid or liquid food).
Study NCT03278704 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: RE only
Description: 8 weeks of supervised training. Three times weekly with no more than two non-consecutive days without exercise.
Study NCT03278704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RE + HIIT
Description: 8 weeks of supervised training. Three times weekly with no more than two non-consecutive days without exercise. Concurrent training: RE followed by HIIT within the same session.
Study NCT01996839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol Etabonate Gel (BID)
Description: One drop of LE gel instilled into the study eye two times per day (BID) for 14 days
Study NCT01996839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol Etabonate Gel (TID)
Description: One drop of LE gel instilled into the study eye three times per day (TID) for 14 days.
Study NCT01996839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle (BID)
Description: One drop of vehicle instilled into the study eye two times per day (BID) for 14 days
Study NCT01996839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle (TID)
Description: One drop of vehicle instilled into the study eye three times per day (TID) for 14 days
Study NCT00228176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimonabant
Description: Tablet, oral administration
Study NCT00228176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Rimonabant)
Description: Tablet, oral administration
Study NCT02575027 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative Radiation Therapy
Description: Undergo 4pi palliative radiotherapy
Study NCT02575027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02575027 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy Treatment Planning and Simulation
Description: Undergo 4pi radiation simulation and planning
Study NCT00749567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150mg daily, continuously, until disease progression or the appearance of unacceptable toxicity
Study NCT00749567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression or the appearance of unacceptable toxicity
Study NCT01620320 — intervention group
Intervention type: OTHER
Intervention: Stress echocardiography
Description: Patients able to exercise will have a treadmill test + echography; the others will have a dobutamine echography.
Study NCT02123472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: Administered Orally
Study NCT02123472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin
Description: Administered Orally
Study NCT01929499 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cytokine-induced killer cells
Study NCT01672177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic disease self-management training
Description: Those in the intervention group will receive two hour long weekly training sessions for seven-eight months (a total of 56 hours of training).
Study NCT01762566 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: xylose
Description: placebo (xylose) will be administered blindly versus wheat in a capsule once
Study NCT01260103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Study subjects in a fasting state receive TMZ orally once a day for five consecutive days (days 1 through 5) at a starting dose of 200 mg/m2/day. Treatment cycles are repeated every 28 days following the first daily dose of TMZ from the previous cycle. In the absence of PD or unacceptable toxicity, subjects continue to receive TMZ for a maximum of 13 cycles.
Study NCT01260103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANP Therapy
Description: Escalating doses of ANP therapy are administered for 52 weeks. If the study subject has an OR or maintains SD, ANP therapy is continued.
Study NCT01414348 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation.
Description: 1 hour / 2x / week for up to 15 sessions